… Financial Results Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic … Officer of ProQR. “This study represents the first clinical evaluation of an Axiomer editing oligonucleotide and … pipeline programs, including ongoing and planned clinical trials, the planned Phase 1 clinical study of for …
… our business, technology, strategy, preclinical and clinical model data, our initial pipeline targets and the … pipeline programs, including ongoing and planned clinical trials, expectations regarding regulatory feedback …
… our business, technology, strategy, preclinical and clinical model data, our initial pipeline targets and the … pipeline programs, including ongoing and planned clinical trials, expectations regarding regulatory feedback …
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting
… studies closely resemble the design of the first in human trial that will focus on target engagement and biomarkers. We … data for our AX-0810 program and to announcing our clinical program candidate later this year, as we progress to … reported in H2 2024, with further detail on design for the clinicaltrial. AX-1412 preclinical proof of concept data and …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in